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Dendritic cellAlternative splicing contributes greatly to the proteomic diversity ofmetazoans. Protein argininemethyltransfer-
ase 5 (PRMT5) methylates arginines of Golgi components and other factors exerting diverse effects on cell
growth/differentiation, but the underlying molecular basis for its subcellular distribution and diverse roles has
not been fully understood. Here we show the detailed properties of an evolutionarily emerged splice variant of
human PRMT5 (PRMT5S) that is distinct from the original isoform (PRMT5L). The isoforms are differentially
expressed among mammalian cells and tissues. The PRMT5S is distributed all over the cell but PRMT5L mainly
colocalizes with Giantin, a Golgi marker. PRMT5 knockdown led to an enlarged Giantin pattern, which was
prevented by the expression of either isoform. Rescuing PRMT5S also increased the percentage of cells with an
interphase Giantin pattern compacted at one end of the nucleus, consistent with its cell cycle-arresting effect,
while rescuing PRMT5L increased that of the mitotic Giantin patterns of dynamically fragmented structures.
Moreover, the isoforms are differentially expressed during neuronal or dendritic cell differentiation, and their ec-
topic expression showed an opposite effect on dendritic cell differentiation. Furthermore, besides their differen-
tial regulation of gene expression, both isoforms also similarly regulate over a thousand genes particularly those
involved in apoptosis and differentiation. Taking these properties together, we propose that their differential ex-
pression and subcellular localization contribute to spatial and temporal regulation of arginine methylation and
gene expression to exert different effects. The novel PRMT5S likely contributes to the observed diverse effects
of PRMT5 in cells.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Alternative precursormessenger RNA (pre-mRNA) splicing greatly in-
creases the proteomic diversity in metazoans [1–3]. It is tightly regulated
in a spatial and temporal manner [2,4,5]. Mutations that lead to aberrant
splicing cause genetic diseases [6,7]. However, the differences between
splice variants of many genes that contribute to the proteomic diversity
in normal cell function and diseases remain to be characterized.
Protein arginine methyltransferase 5 (PRMT5) catalyzes the sym-
metric dimethylation of arginines of a diverse group of proteins
[8–14], contributing to the regulation of gene expression, snRNP bio-
genesis, maintenance of stem cell pluripotency and promotion of cell& Pathophysiology, College of
itoba, Winnipeg, MB R3E 0J9,proliferation [9,10,14–19]. The dynamic cytoplasmic or nuclear localiza-
tion of PRMT5 during early embryonic development is essential for the
maintenance of pluripotency or cell fate determination [10]. Particularly
in the cytoplasm, PRMT5 is known to localize to the Golgi apparatus
(GA) andmethylates GM130, a critical factor for Golgi ribbon formation
[20]. During mitosis, GA undergoes dynamic structural changes, with a
compacted structure near one end of the nucleus in the interphase
and various extents of fragmentation during mitosis [21–23]. PRMT5
co-localizeswithGAmarkers and is thought to be required for themain-
tenance of Golgi structure at interphase throughmethylation of GM130
[20]. However, the cell cycle-speciﬁc structural changes of Golgi due to
modulation of cell cycle by PRMT5 have not been considered.
Here we report the detailed properties of a recently identiﬁed
shorter PRMT5 isoform (PRMT5S) that evolutionarily emerged through
exon 3 and partial exon 4 skipping [24,25]. These properties are differ-
ent from that of the original isoform (PRMT5L), particularly expression
among cell lines/tissues, distinct subcellular localization during cell
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gene expression.
2. Materials and methods
2.1. RT-PCR
Semi-quantitative RT-PCR of endogenous PRMT5was performed as
described previously [24,26], using the primer pair hPRMT5F (5′-
CAGGAACCTGCTAAGAATCG-3′) and hPRMT5R (5′-GCCAGTGTGGATGT
GGTTG-3′). Human tissue-speciﬁc total RNA was purchased from
Clontech Co. (Cat No. 636643), for which more information can be
found at the product page of the company website (http://www.
clontech.com). For PCR of GAPDH as an RNA loading control, we used
the upstream GAPDHF (5′-CTTCATTGACCTCAACTACATGGTT-3′) and
downstream GAPDHR (5′-GCTCCTGGAAGATGGTGATG-3′) primers.
Both primer pairs are compatible with human, rat or mouse genes.
2.2. Plasmid construction
PRMT5 L or S open reading frames were ampliﬁed by PCR from
PRMT5 cDNA clone (ID 3833019, OPEN Biosystems) using Phusion
High-Fidelity DNA polymerase, and cloned between EcoRI and BglII re-
striction sites of pCMV-Myc vector. PRMT5L-Flag construct was obtain-
ed by cloning the open reading frame along with C-terminal Flag tag
between XhoI and ApaI restriction sites of pcDNA3.1 vector. PRMT5 L
or S was sub-cloned into vector cppt2E for lentivirus-based expres-
sion [27]. The constructs were conﬁrmed by sequencing. We purchased
plasmid pLKO.1 containing shRNA against human PRMT5 3′UTR
(shPRMT5, clone ID TRCN0000107085, mature antisense sequence
TATTCCAGGGAGTTCTTGAGG) from OPEN Biosystems.
2.3. Cell culture and ectopic expression of Myc-PRMT5 isoforms
HeLa and HEK293T cells were cultured and transfected with Myc-
tagged PRMT5 plasmids for overexpression as described previously
[28]. MDA-MB-231, BT20, U2OS and B35 cells were cultured in DMEM
containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomy-
cin/glutamine (PSG) solution (Invitrogen). PC12 cells were grown in
DMEM containing 10% horse serum (HS), 2.5% FBS and 1% PSG. GH3
cells were grown in F-10 media containing 10% HS, 2.5% FBS and 1%
PSG. H9 cells were obtained from Wicell and approved for use by the
local ethics board and the StemCell Oversight Committee of the Canadi-
an Institutes of Health Research. These cells were cultured and RNA ex-
tracted as described previously [29]. LA-N-5 and MAL (lymphocytes
from an ataxia telangiectasia patient [30]) cells were cultured in RPMI
containing 10% fetal bovine serum and 1% PSG. For LA-N-5
differentiation, cells were fed with fresh media containing 5 μM 13-
cis-retinoic acid (RA, R3255, Sigma-Aldrich) every 48 h for 4 days
[31–33]. Murine bone marrow-derived dendritic cells (BMDCs) were
generated from bone marrow (BM) precursors as previously described
[34]. Brieﬂy, mouse BM cells collected from the femura and tibiae
were cultured in RPMI 1640 (HyClone) medium containing PSG
(Gibco), 2-ME, 10% FBS (HyClone), and 20 ng/ml GM-CSF (PeproTech).
Culture mediumwas changed every 2 days and cells were collected at 7
time points over the course of differentiation for RNA analysis.
For ectopic expression of PRMT5L or S in BMDCs, we transduced pre-
cursor cells with either one of the protein-expressing viral vectors. Irrel-
evant EGFP-expressing lentiviral vector (Cppt2E) was used as control
[34]. Differentiated DCs with ectopic expression of proteins were ﬁxed
and immunostained.
2.4. RNA interference and rescue
For splice variant speciﬁc knock down of PRMT5 we synthesized
siRNAs targeting PRMT5S-speciﬁc sequence TGTCAGGAAGGGCTTTCCTor PRMT5L-speciﬁc sequence CTCCATGGATTCGTCCAGA. We transfected
HeLa or MDA-MB-231 cells with 360 pmol of siRNA in 6 well plates.
Cells were harvested after 60 h of transfection for RNA analysis, immuno-
precipitation or immunostaining.
Lentivirus transduction for PRMT5 knock down and rescue with ei-
ther one of the isoforms was carried out as described [35]. HeLa cells
were transduced with shPRMT5-containing virus followed by another
transduction along with rescue protein expressing viruses after 36 h.
Cellswere split andﬁve days after ﬁrst transduction, harvested forwest-
ern blot and immunostaining.
2.5. Western blots, immunoprecipitation and immunostaining
Western blots and immunostaining were performed as previously
described [36]. Anti-Myc, anti-β-actin, anti-Giantin, anti-PRMT5
(SC2232), anti-PRMT5 (SC136202) and anti-nucleolin were purchased
from Santa Cruz Biotechnology Inc. Anti-PRMT5 (EPR5772) was pur-
chased from Abcam, anti-Flag from Sigma and Cy3 conjugated anti-
CD40 from Biolegend. For immunostaining, we used primary antibodies
at dilution of 1:100 and Texas-Red or FITC conjugated secondary anti-
bodies or Cy3 conjugated CD40 primary antibody at 1:1000. 4′,6-
diamidino-2-phenylindole (DAPI)was used at 1:5000 dilution to visual-
ize DNA. Immunoprecipitation was performed as described previously
[37], using anti-PRMT5 (EPR5772) and whole cell lysates prepared in
radioimmune precipitation assay (RIPA) buffer.
2.6. RNA sequencing
We transfected HEK293T cells with Myc-PRMT5L or -PRMT5S con-
taining plasmids. Total RNA was extracted from triplicates of control
(non-transfected) and transfected cells, and submitted to McGill Uni-
versity and Genome Quebec Innovation Centre, where RNA samples
were reverse transcribed using random primers for library preparation
and subjected to protocols for sequencing using Hiseq 2000/2500 se-
quencer. We obtained 67 ± 1.9 million uniquely mapped reads on
average for each sample. The gene expression analysis was done using
DEseq and edgeR [38,39]. We used edgeR-adjusted p values of less
than 0.05 for further analysis. For functional clustering of differentially
expressed genes we used online tool DAVID 6.7 with the highest strin-
gency and p value b 0.05 [40,41].
3. Results
3.1. Differential expression of PRMT5S in mammalian cells and tissues
In PRMT5S, exon 3 together with the 5′ 46 nt of exon 4 is skipped
(Fig. 1A). We measured the PRMT5 variants among cell lines using
low cycle number semi-quantitative polymerase chain reaction after re-
verse transcription (RT-PCR, Fig. 1B). In mRNA transcripts from human
cell lines U2OS, HEK293T, MDA-MB-231, HeLa, BT20, H9 and MAL,
PRMT5S levels range from 10% (±2, n = 3, in molar percentage, same
as following levels) to 43% (±3, n = 3) (lanes 2–8). In rat cell lines
PC12, B35 and GH3, no PRMT5S was visible in the agarose gels (lanes
9–11). It was only visible when a more sensitive RT-PCR assay using
32P-labeled primer and denaturing PAGE gels was used (data not
shown). Therefore, the PRMT5 variants are differentially expressed
among these mammalian cell lines.
To determine the distribution of the novel isoform PRMT5S in
humans, we obtained total RNA from 20 different tissues and measured
its abundance using semi-quantitative RT-PCR. The result indicates that
PRMT5S is differentially expressed among the tissues with varying
molar percentages ranging from 8% in the spinal cord to 37% in the kid-
ney (Fig. 1C, lanes 2–21). Cerebellum, testis, thymus and small intestine
also have substantial amount of this variant (22–33%, lanes 4, 16, 17 and
20, respectively). This data thus suggests that the expression of PRMT5S
is regulated in a tissue-speciﬁc manner.
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Fig. 1.Differential alternative splicing of PRMT5 exon 3 and 5′ end of exon 4. A, Diagram of PRMT5 pre-mRNA around exon 3 indicating its alternative splicing (not to scale). Arrow heads:
positions of PCR primers. B, Differential expression of PRMT5S in mammalian cell lines. Shown are representative images of agarose electrophoresis gels of exon 3 and partial exon 4-in-
cluded or -excludedRT-PCR products as conﬁrmed by sequencing (lanes 2–11). C (lane 1): PCR control. Human cells: U2OS (osteosarcoma), 293T (embryonic kidney tumor),MDA (breast
cancer MDA-MB-231), HeLa (cervical cancer), BT20 (mammary carcinoma), H9 (embryonic stem cells) and MAL (lymphocytes). Rat cells: PC12 (pheochromocytoma), B35 (neuroblas-
toma) andGH3 (pituitary epithelial-like tumor). C, Differential expression of PRMT5S among20 human tissues. Upper panel, representative images of agarose electrophoresis gels of semi-
quantitative RT-PCRproducts of PRMT5L or PRMT5S from the 20 human tissues as indicated. Images of the PRMT5S productswith longer exposure and higher contrast of the same gels are
shown below. The average molar percentages of PRMT5S from three separate PCR reactions are indicated below each lane. Lower panel, RT-PCR products of GAPDH, as an RNA loading
control. C: RT-PCR control without reverse transcriptase. *: an unidentiﬁed product in skeletal muscle and fetal liver. D, Expression of PRMT5 variants in rat tissues. Shown are images
as in B–C of PRMT5 spliced products and GAPDH from different rat tissues (lanes 2–11). C (lane 1): PCR control.
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different rat tissues (Fig. 1D). Consistent with our observations in the
above rat cell lines, the PRMT5S in rat tissues was not visible either in
agarose gels.
Together these data indicate that PRMT5S is differentially expressed,
and is mainly in human cells and tissues.
3.2. Distinct subcellular localization of PRMT5S from that of PRMT5L
To examine the localization of PRMT5 variants, we performed
immunostaining experiments. In HeLa cells, Myc-tagged PRMT5L
localized mainly around the nucleus, similar to that observed byothers [20], while PRMT5S was more diffusely distributed in both
the nucleus and cytoplasm (Fig. 2A–B). In HEK293T cells, similar
distribution patterns and differences were observed for the
expressed variants (Fig. 2B). Therefore their differential subcellu-
lar distribution is consistent between the two different types of
cells.
The localization of exogenous Myc-PRMT5L also overlaps with a
PRMT5L that is Flag-tagged at the COOH-terminus, when co-expressed
and -immunostained with the respective tag antibodies in the same
HeLa cells (Fig. 2C). Therefore, the punctate distribution of the Myc-
PRMT5L is a property of the PRMT5L protein rather than that of the pep-
tide tags used.
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Fig. 2. Expression and intracellular localization of exogenous PRMT5 isoforms. A, Expres-
sion of exogenous Myc-PRMT5L or S in HeLa cells. Western blot of HeLa cell lysates
transfected with Myc-PRMT5L or S showing the expression of either one of the isoforms.
B, Intracellular localization of exogenous PRMT5 isoforms. Shown are immunostained
HeLa (upper panel) or HEK293T (lower panel) cells transfected as in A, using anti-Myc.
DAPI staining of nuclei ismergedwith theMyc signals in the last column. Non-transfected
control cells are shown in the top row of each panel. C, Subcellular localization of exoge-
nous PRMT5 containing a different tag. Shown are HeLa cells co-transfected with Myc-
or Flag-tagged PRMT5 and immunostained using anti-Myc or anti-Flag. DAPI staining of
nuclei, Flag and Myc signal are merged in the last image.
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out splice variant-speciﬁc RNA interference using siRNAs targeting exon
3 (PRMT5L-speciﬁc) or the junction of exons 2 and 4 (PRMT5S-speciﬁc).
We transfected HeLa cells with scrambled or either of the splice variant
speciﬁc siRNAs. These PRMT5 siRNAs decreased the level of speciﬁc tar-
get transcripts as veriﬁed by RT-PCR, from 33% to 6% for PRMT5S
(Fig. 3A, lower band, p = 2.1E−6, n = 3, lane 3 compared to lane
2) and from 67% to 39% for PRMT5L (upper band, p = 1.5E−4, n = 3,
lane 4 compared to lane 2). Thus, the siRNAs speciﬁcally reduced either
one of the endogenous PRMT5 variants.
To conﬁrm the variant-speciﬁc knockdown of endogenous proteins,
we carried out western blots of immunoprecipitated PRMT5 from pro-
tein lysates of siRNA-transfected HeLa orMDA-MB-231 cells. Consistent
changes were observed in both cell samples but the MDA sample
showed a slightly higher relative level of PRMT5S-like band in the
assay (Fig. 3B). The PRMT5L-speciﬁc siRNA decreased the ratio of
PRMT5L/S-like from 3.5 to 2.2 (lane 3 compared to lane 2) whereas
PRMT5S-speciﬁc siRNA increased the ratio to 5.1 in the MDA cells
(lane 4 compared to lanes 2 and 3). Thus, the ratio of the protein iso-
forms change consistently as the mRNA variants upon variant-speciﬁcsiRNA knockdown, supporting the identity of the PRMT5S-like band as
endogenous PRMT5S protein in cells.
We next examined the localization of endogenous PRMT5 in HeLa
cells by immunostaining of the remaining isoforms (Fig. 3C). In most
of the control siRNA-transfected cells (91% ±2.5%, n = 3 groups, 100
cells each group, same in the following localization analysis in this ﬁg-
ure), the endogenous PRMT5 staining pattern showed punctate spots
with light diffusing backgrounds (Fig. 3C, siC panel), consistent with
the presence of both the long and short isoforms. Transfection of
PRMT5L-speciﬁc siRNA signiﬁcantly reduced the number of strong
spots and led to more diffuse distribution in about 59% (±4%, n = 3
groups) of cells (Fig. 3C, siPRMT5L panel). In contrast, transfection of
PRMT5S-speciﬁc siRNA created bright spots and simultaneously re-
duced the diffusing backgrounds in 68% (±3%, n = 3 groups) of cells
(Fig. 3, siPRMT5S panel). These changes were also conﬁrmed by immu-
nostainingwith a different PRMT5 antibody under highermagniﬁcation
(Fig. 3D), with the siPRMT5L reducing the punctate staining and
siPRMT5S reducing the diffusing staining signals from the control
siRNA samples. Thus, the localization changes of endogenous PRMT5
isoforms after splice variant-speciﬁc knockdown are consistent with
the differences between the Myc-PRMT5 isoforms.
Together, these data support that the exogenous and endogenous
PRMT5 isoforms exhibit consistently different subcellular localization.
Speciﬁcally, the PRMT5S localizes all over the cell, distinct from the
highly punctate localization of the PRMT5L.
3.3. PRMT5S has an opposite effect on Golgi structure during cell cycle
The distribution of PRMT5L mainly around the nucleus has been
shown to colocalize with the Golgi markers P230, ManII, GM130, NSF,
GRASP55 and Giantin, and it methylates GM130 to regulate Golgi struc-
ture [20]. The Golgi marker localization is cell cycle-dependent, chang-
ing from a compacted structure beside one end of the nucleus in
interphase to dynamic fragmented structures during mitosis [21–23,
42,43]. Moreover, PRMT5L itself also promotes mitosis [12,18,19]. We
thus examined the localization of the PRMT5S and PRMT5L relative to
Giantin during cell cycle in HeLa cells without or with PRMT5 knock-
down/rescue to dissect the relationship between the PRMT5 isoforms
and Golgi structures (Fig. 4A).
The endogenous PRMT5 exhibited cell cycle-dependent changes in
subcellular localization (Fig. 4B, upper/control panel). Particularly the
bright areas overlap with Giantin. Interestingly, PRMT5 knockdown re-
sulted in a 1.6 fold (±0.1) increase in the area of the compact Giantin
staining in the interphase as compared to that in control cells (p =
2.6E−06, n = 3 experiments, 300 cells each experiment, Fig. 4B, 2nd/
shPRMT5 panel). The knockdown also promoted more diffusing distri-
bution of Giantin at metaphase and to a lesser extent at subsequent
stages. PRMT5 thus appears to be essential for the compactness of the
Golgi apparatus during cell cycle.
In PRMT5 knockdown cells expressing the rescue isoforms, Myc-
PRMT5L showed dynamic patterns of localization during cell cycle
(Fig. 4B, 3rd panel, shPRMT5 + MycPRMT5L). This pattern overlaps
mostly with that of Giantin. In contrast, the Myc-PRMT5S is more
homogenously distributed all over the cell during cell cycle
(Fig. 4B, bottom panel, shPRMT5 + MycPRMT5S), with its brightest
areas overlapping with Giantin as well. Moreover, both rescuing
isoforms eliminated the slight changes by PRMT5 knockdown and
restored the compactness of the Golgi structures similar to that of
the control cells.
Together, the knockdown/rescue data indicate that the PRMT5 iso-
forms show distinct and dynamic co-localization with the Golgi marker
Giantin during cell cycle and they are likely required for the compact-
ness of Golgi structure.
We next examined the effect of PRMT5 isoforms on the prevalence
of cells containing interphase compacted or mitotic dynamic Golgi
structures. In overexpression experiments, MycPRMT5L increased the
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Fig. 3.Differential subcellular localization of endogenous PRMT5 isoforms based on splice variant-speciﬁc RNA interference and immunostaining. A, Effect of splice variant-speciﬁc knock-
down on endogenous PRMT5 variants. Shown are representative images of agarose electrophoresis gels of RT-PCR products of endogenous PRMT5 variants or GAPDH from HeLa cells
transfected with scrambled control siRNA (siC) or splice variant-speciﬁc siRNA (lanes 2–4). C (lane 1): PCR control. B, Effect of splice variant-speciﬁc knockdown on endogenous
PRMT5 protein isoforms. Shown is the western blot of immunoprecipitated PRMT5 fromMDA-MB-231 cells transfected as in A (lanes 2–4). PRMT5 bands were not detectable in immu-
noprecipitation controls without PRMT5 antibody (lane 1). C, Effect of splice variant-speciﬁc knock-down on endogenous PRMT5 localization. Shown are representative images of HeLa
cells transfectedwith control or PRMT5 splice variant-speciﬁc siRNAs and immunostained using anti-PRMT5 (SC136202). Control cells without PRMT5 antibody are shown in the top row.
Enlarged pictures of the PRMT5 signals of example cells are in the right column and pointed by a white arrow head in the panel withmultiple cells. Nuclei stained with DAPI are in the left
column. D, Representative higher magniﬁcation images of HeLa cells transfected as in C and immunostained with anti-PRMT5 (SC22132). DAPI-stained nuclei are merged with PRMT5
signal in the right column. Control cells without PRMT5 antibody are shown in the top row.
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posite effect (Fig. 4C, left panel). Knock-down of endogenous PRMT5 in-
creased the percentage of cells with interphase compact Golgi from
43.5% to 63.2% (±4.6%, p=0.008, n=3, 300 cells each, same in the fol-
lowing analysis of Golgi structures in this ﬁgure). Rescue with
MycPRMT5S further increased this cell population to 76.4% (±5.5%,
p = 0.002). In contrast, rescue with MycPRMT5L had the opposite ef-
fect: it decreased this cell population to 29.5% (±3.9%, p = 0.02)
(Fig. 4C, right panel). These observations are consistent with the oppo-
site effects of the PRMT5 isoforms on mitosis [12,18,19,25]. Thus,
PRMT5S has an opposite effect on the number of cells with interphase
or mitotic Golgi structure compared to PRMT5L.3.4. PRMT5 isoforms are differentially expressed during differentiation and
PRMT5S has an opposite effect on the differentiation of dendritic cells
The differential expression, localization and effect on cell cycle and
Golgi structure suggest that the two isoforms may have more down-
streameffects on cells.We then explored the role of the PRMT5 isoforms
during cell differentiation.We induced LA-N-5 human neuroblastoma cells differentiation
using 13-cis-retinoic acid (RA), as reported by others [31–33]. Upon dif-
ferentiation, the percentages of exon skipping signiﬁcantly decreased
from 46% to 34% (Fig. 5A–B, p = 0.003, n = 3). Thus, PRMT5 variants
are differentially regulated during neuronal differentiation.
We also examined the expression of the variants in mouse dendritic
cells (DCs). DCs are derived from hematopoietic stem cells, which un-
dergo tightly regulated lineage commitment, differentiation and matu-
ration processes in vivo [44–46]. In vitro, a well-established culture
condition has been used to generate dendritic cells from adherent
bone marrow cells in the presence of GM-CSF cytokine [34]. We used
the in vitro differentiating DCs as a primary cell model to examine ex-
pression of the PRMT5 isoforms. The bone marrow precursor cells did
not express any PRMT5 isoform (Fig. 5C, lane 2), while differentiating
DCs started to express detectable PRMT5L only on day 3 and at higher
levels during the following days (Fig. 5C, lanes 5–7). This suggests that
PRMT5 is expressed in a variant-speciﬁc and differentiation time-
dependent manner in DCs.
We then used this in vitro differentiation system to examine the
effect of ectopic expression of either one of the MycPRMT5 isoforms
on the differentiation/maturation of DCs. The precursor cells were
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PRMT5 and rescue with PRMT5L or S in HeLa cells using lentiviral transduction of shRNA and expression plasmids. B, Representative images of HeLa cells treated as in A and immuno-
stained using anti-PRMT5 (EPR5772) and anti-Giantin at different stages of cell cycle. DAPI-stained nuclei are merged with PRMT5 and Giantin signals in the bottom row of each
panel. Pro: Prophase; Meta: Metaphase; Ana–Telo: Anaphase to Telophase. C, Bar graph showing the percentages of HeLa cells with interphase or mitotic Giantin patterns. Interphase:
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HeLa cells overexpressing either one of the PRMT5 isoforms. Right panel: knockdown/rescue cells treated as in A. ***: p b 0.001. Below are the representative images of HeLa cells treated
as in A and immunostained with Giantin antibody.
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PRMT5L during the in vitro differentiation of DCs, which was deﬁned
by the expression of CD40. Non-transduced and mock-transduced
cells showed about 10% CD40 positive cells while the PRMT5L-
transduced cells showed only 6% CD40 positive cells (±1.7%, p =
0.01, n = 3 groups, 300 cells/group, same in the following analysis
of CD40). In contrast, the PRMT5S-transduced cells showed about
two-fold increase (±2.5%, p = 8.4E−05) of CD40 positive cells as
compared to controls (Fig. 5D–E). Thus, ectopic expression of the
PRMT5S variant in precursor cells promotes the differentiation of
DCs, while PRMT5L inhibits it.3.5. PRMT5 isoforms regulate genes involved in various cellular processes
including apoptosis and differentiation
In our recently reported RNAseq data, we have showed that the
two isoforms differentially regulate a group of genes including cell
cycle-arresting genes preferentially regulated by PRMTS to promote
cell cycle arrest whereas PRMT5L promotes mitosis [25]. To identify
genes that are similarly regulated by both isoforms, we analyzed fur-
ther the RNAseq data and identiﬁed 1636 genes in HEK293T cells ex-
pressing either isoforms with signiﬁcant difference of the number of
reads from the control sample (p b 0.05). The number of reads of
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that methylation by PRMT5 could either enhance or inhibit the ex-
pression of target genes.
We tested the expression of 25 genes by RT-PCR. Of the 22 genes
with correct PCR products, all were conﬁrmed to have the same direc-
tion of changes as predicted by the reads from RNAseq analysis [25].
We used the minimal number of reads detectable by RT-PCR (42.4 on
average, of 9 samples) as a cut-off value, which resulted in 1072 genes
with at least 42 reads. We used these genes for functional clustering
analysis using DAVID [40].
These regulated genes clustermost signiﬁcantly for six functions: ho-
meobox, phosphorylation, differentiation, apoptosis, axonogenesis and
transcription (Table 1). For instance, 38 genes including BCL2 (B-cell
lymphoma 2) and CASP10 (Caspase 10, apoptosis-related cysteine pepti-
dase) in apoptosis and21 genes includingNRXN3 (Neurxin-3-alpha) andSLIT2 (Slit homolog 2 protein) in axongenesis. Other functions related to
the DC differentiation include innate immune response (p = 0.01) and
semaphorins (p = 0.01). For example, the Semaphorin family of genes
SEMA3A, D, E, G, and 6D are down-regulated by the PRMT5 isoforms. In-
terestingly, SEMA4D, which is required for the maturation of dendritic
cells [47,48], is up-regulated by 1.5 times (±0.1, n = 3, p = 0.02).
These clusters are consistent with the diverse functions of PRMT5 in
cell growth/mitosis and differentiation [9,10,14–19]. Therefore, the con-
trol of the expression of genes of different pathways by PRMT5 is likely
part of a program of changes underlying its effect on cell properties.
While the differentially regulated target genes by the two PRMT5 iso-
forms may contribute to their differential effects on cell mitosis and dif-
ferentiation [25], the commonly regulated ones perhaps contribute to
the control of common targets in cellular processes such as the dynamic
changes of Golgi structure and differentiation.
Table 1
Functional Clustering of genes commonly regulated by PRMT5L and PRMT5S. Genes with well-known functions in their category are highlighted in bold.
Category p-Value Genes # of
genes
Homeobox .0003 POU6F1, HOXA13, PRRX1, ZEB2, PAX3, PDX1, HDX, HOXA3, LHX2, HLX, HOXA6, POU2F2, HOXA10, POU3F2, TLX3, BARHL2, ISL1, HOXD9,
HOXB4, DLX1, MSX1, HOXB8, HOXB5, HOPX, HMX3
25
Phosphorylation .0004 HMGCR, PDGFA, CSF1, TGFB3, TRIB3, PRDX2, ZEB2, BDKRB2, KIT, TRIB2, LATS2, SPRY4, IL11, LIF, SPRY2, DUSP19, NOD2, CDKN2B, BCL2,
DUSP16, SPRED2, RAPGEF3, FAM129A, PPP1R14C, FRS2, MAP2K6, PPP1R14A, GHR, BCL10, SPHK1, PIM1, CDK5, CDC25A, PROK2, CDKN1A,
CCND1, CNTF, CCND2, GADD45G, IL12A, DUSP8, GADD45A
42
Differentiation .0009 S100A4, FGF19, ALDH1A2, RET, BCL2, CYP26A1, ZEB2, PAX3, ISL1, GDNF 10
Apoptosis .001 PTGS2, HOXA13, ZMAT3, APH1B, TGFB3, SMNDC1, PCBP4, SQSTM1, AEN, BCL2, TICAM1, TNFRSF19, BCL3, INPP5D, RARB, PHLDA3, FOSL1,
DEDD2, MAP2K6, KCNMA1, BCL10, AIFM2, KLF10, NR4A1, CDK5, DDIT3, CASP10, CDKN1A, EPHA7, NME3, BBC3, ENDOG, UBC, IL12A, RIPK2,
NGFR, DCUN1D3, TP53INP1
38
Axonogenesis .001 RAB3A, NRXN3, ISL1, CDK5, CXCL12, SLIT2, NUMBL, EPHA4, EPHA7, UNC5A, LHX2, BCL2, UBC, ROBO2, VCAN, SEMA3A, NGFR, UNC5C,
SLITRK5, ETV4, GFRA3
21
Transcription .001 IRAK2, PTHLH, NOD2, ID1, PIM1, PRDX2, CAT, PROX1, DDIT3 9
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PRMT5 is known to have diverse functions in both the cytoplasm
and nucleus in cells but the source of this functional diversity has not
been fully understood. Our data demonstrate that PRMT5 isoforms cre-
ated by exon 3/4 alternative splicing are differentially expressed among
different cells and during differentiation. They also exhibit distinct sub-
cellular localization and control the compactness of the Golgi apparatus
during cell cycle. Moreover, these two isoforms show opposite effects
on prevalence ofmitotic Golgi and dendritic cell differentiation, perhaps
involving the control of the expression of a group of genes.
PRMT5 has complex roles in cells. For instance, it maintains embry-
onic stem cell pluripotency during development [10,17], but on the
other hand also controls the expression of critical genes in erythroid dif-
ferentiation [49]. These seemingly opposite processes are thought to be
carried out by the same PRMT5 protein. The discovery of the PRMT5S
and its distinct properties from PRMT5Lmakes it worthwhile to explore
the presence and potential role of this novel variant in these cellular
processes.
PRMT5S contains the intactmethyltransferase domain,which is con-
sistentwith its capability tomaintainmethylation of histone 4, a PRMT5
target [25]; however, its skipped region corresponds to a part of N-
terminal TIM barrel domain, which interacts with MEP50, a cofactor of
PRMT5 [25,50]. The interactionwithMEP50 canmediate both substrate
recognition and regulation of methyltransferase efﬁciency of PRMT5
[50–53]. Structural insights into PRMT5 particularly in complex with
MEP50 indicate that the PRMT5S-skipped region is located in close
proximity to the interface of these proteins [51,52,54]. Besides MEP50,
the N-terminal region of PRMT5 is also involved in interactions with
RioK1, pICln and Menin which can modulate PRMT5 activity and sub-
strate speciﬁcity [50,55,56]. Therefore, altered interactions of PRMT5S
with these proteins can contribute to the differential properties and
functional consequences of this variant. Moreover, the N-terminal re-
gion of PRMT5 seems to harbor non-canonical nuclear exclusion signals
[57], likely disrupted in PRMT5S resulting in a distinct diffusing localiza-
tion pattern (Figs. 2–4). Interestingly, PRMT5 exhibits subcellular
localization-speciﬁc effects in several cell types [10,57–62]. Thus, the po-
sition of the region skipped in PRMT5S could potentially affect the pro-
tein–protein interaction, enzyme efﬁciency and subcellular localization
of this variant leading to differential functional consequences. It'd be in-
teresting to explore if the PRMT5S properties could help explain at least
some of the diverse effects of PRMT5 in cells observed previously.
The role of PRMT5 in maintaining the compactness of Golgi struc-
tures is supported by the increased area of GolgimarkerGiantin at inter-
phase and more diffusing distribution during mitosis upon PRMT5
knock-down (Fig. 4B). This role is carried out by either of the PRMT5 iso-
formswith a similar effect (Fig. 4B). Besides their common effect on the
compactness of the Golgi apparatus, the PRMT5 isoforms also exhibited
opposite effects on the distribution of Golgi structures speciﬁc for the
different phases of cell cycle. We observed the increase of interphaseGolgi structures compacted near one end of the nucleus upon PRMT5
knockdown in cells expressingmainly PRMT5L (Figs. 3–4). Interestingly
in rescuing experiments, the two PRMT5 isoforms have opposite effects
on the percentage of the interphase/mitotic Golgi structures (Fig. 4),
though they both have proteinmethylation capability [25]. The different
effects are consistent with the increase of the percentage of interphase
cells by PRMT5S andmitotic cells by PRMT5L, likely through their differ-
ential control of a group of genes involved in cell cycle arrest in similar
experiments [25].
The presence of PRMT5S all over the cells indicates that it might be a
better candidate for the methylation of nuclear proteins such as his-
tones and p53 [9,13,19], as well as cytoplasmic proteins outside of the
Golgi apparatus [11,63,64].
In summary, we show here that the two PRMT5 variants have dis-
tinct expression, localization and effects on Golgi structure and function
in cell differentiation. This adds to the repertoire of PRMT proteins by
providing a variant candidate for the diverse and often complex effect
of PRMT5 in cells.
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